AzurRx BioPharma (NASDAQ:AZRX) Shares Up 9.1%

Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) shot up 9.1% on Monday . The stock traded as high as $0.77 and last traded at $0.72, 320,267 shares traded hands during mid-day trading. An increase of 64% from the average session volume of 195,714 shares. The stock had previously closed at $0.66.

Several research firms have weighed in on AZRX. Maxim Group set a $3.00 price target on AzurRx BioPharma and gave the stock a “buy” rating in a research note on Tuesday, October 15th. HC Wainwright set a $5.00 price target on AzurRx BioPharma and gave the stock a “buy” rating in a research note on Friday, October 18th. Six research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus target price of $7.10.

The firm has a market capitalization of $17.26 million, a P/E ratio of -0.81 and a beta of 2.12. The company has a 50 day simple moving average of $0.68 and a two-hundred day simple moving average of $1.19.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in AzurRx BioPharma by 57.6% in the 2nd quarter. BlackRock Inc. now owns 42,313 shares of the company’s stock worth $72,000 after purchasing an additional 15,463 shares during the period. Royal Bank of Canada bought a new position in AzurRx BioPharma in the 2nd quarter worth approximately $48,000. JPMorgan Chase & Co. bought a new position in AzurRx BioPharma in the 2nd quarter worth approximately $57,000. Virtu Financial LLC bought a new position in AzurRx BioPharma in the 3rd quarter worth approximately $51,000. Finally, Vanguard Group Inc. boosted its stake in AzurRx BioPharma by 255.0% in the 2nd quarter. Vanguard Group Inc. now owns 260,306 shares of the company’s stock worth $443,000 after purchasing an additional 186,985 shares during the period. Institutional investors and hedge funds own 9.52% of the company’s stock.

AzurRx BioPharma Company Profile (NASDAQ:AZRX)

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Recommended Story: Do equity income investments outperform growth and income investments?

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.